Bioinvent International Ab · OMXSTO:BINV
Bioinvent International Ab — Investor Presentation (October 2026)
49 slides from Bioinvent International Ab's investor presentation, October 2026
Slide 1: The Next-Generation Immunotherapy of Cancer
THE NEXT-GENERATION IMMUNOTHERAPY OF CANCER October 2026
Slide 2: Disclaimer
Disclaimer This presentation is not a prospectus or other offer document and has not been approved by any regulatory authority in any jurisdiction. The information contained in this presentation has been prepared solely for information purposes. It is not intended for potential investors and does no
Slide 3: BioInvent is Developing the New Standard of Care for Recurring Ovarian Cancer
BioInvent is Developing the New Standard of Care for Recurring Ovarian Cancer - $1.7 billion in estimated peak sales 3
Slide 4: Swedish clinical-stage biotech developing first-in-class immune-modulating antibodies
We are a Swedish clinical-stage biotech developing first-in-class immune- modulating antibodies to treat cancer o Cancer immunotherapies with novel MoAs and excellent safety profiles 4 Ongoing Clinical o Phase 2 trials ongoing with early evidence of efficacy Programs o History of successful partners
Slide 5: Function F.I.R.S.T Enables Discovery of New Oncology Targets and Antibodies
Function F.I.R.S.T Enables Discovery of New Oncology Targets and Antibodies 5
Slide 6: BioInvent has First-in-class Clinical Assets Advancing Across Multiple Indications
BioInvent has First-in-class Clinical Assets Advancing Across Multiple Indications Compound/Indication Phase 1 Phase 2a Phase 2b Milestone ➔ Complete Phase 2a TNFR2 Ovarian cancer Ongoing data H1 2027 Pembrolizumab1 Ovarian cancer Planned ➔ First Phase 2a data Pembrolizumab1 + Paclitaxel expected en
Slide 7: Anti-TNFR2
ANTI-TNFR2 BI-1808 in Ovarian Cancer BI-1808 in T-cell Lymphoma 7
Slide 8: BI-1808's Differentiated Mechanism of Action
BI-1808’s Differentiated Mechanism of Action Depletes Tregs and activates macrophages to induce CD8+ T cell antitumor immunity Mårtensson et al, BioRxiv + anti-PD-1 Mårtensson, et al (Cancer Research https://doi.org/10.1158/0008-5472.CAN-26-0274) 8
Slide 9: BI-1808 Clinical Trial Design Phase 1/2a (KEYNOTE-D20)
TNFR2 BI-1808 BI-1808 Clinical Trial Design Phase 1/2a (KEYNOTE-D20) Phase 1 Phase 2a All Cancer Types Tissue-specific Cohorts Dose Escalation Signal Seeking Randomization mTPI2 design n=12 subjects per cohort n=10/20 subjects per cohort between 1000 mg and 250/500 mg BI-1808 1000 mg 6 additional 1.
Slide 10: BI-1808: Strong Single Agent Activity in Solid Tumors
TNFR2 BI-1808 BI-1808: Strong Single Agent Activity in Solid Tumors Link to poster • Heavily pre-treated, end-of the-line patients ASCO 2024 Poster Presentation • 1 complete response (CR) in ovarian cancer • 1 partial response (PR) in GIST that continued through the full study treatment. Multiple bi
Slide 11: BI-1808 Single Agent Case Study: Complete Response in Ovarian Cancer
TNFR2 BI-1808 BI-1808 Single Agent Case Study: Complete Response in Ovarian Cancer Baseline 2 months 63-year-old patient with ovarian cancer, Stage IIIA at diagnosis, entered the study with PD. Four previous lines of treatment: • Paclitaxel/carboplatin • Carboplatin/doxorubicin • Olaparib • Bevacizu
Slide 12: BI-1808 Single Agent Case Study: Robust PR in a Patient with GIST
TNFR2 BI-1808 BI-1808 Single Agent Case Study: Robust PR in a Patient with GIST* Baseline Follow-up 13 months 55-year-old male patient with GIST, who presented with clinical PD for more than six months with multiple metastatic lesions. 12 previous lines of therapy. Pre-dose Week 5 Blue = DAPI Blue =
Slide 13: BI-1808 in Ovarian Cancer
BI-1808 in Ovarian Cancer ‘SBiolnvent | 13
Slide 14: BI-1808 + Pembrolizumab Achieves 24% ORR in Recurrent Ovarian Cancer
TNFR2 BI-1808 BI-1808 + Pembrolizumab Achieves 24% ORR in Heavily Pretreated Recurrent Ovarian Cancer Patients Chemotherapy-free Regimen | ESMO 2026 Best Poster Award, Investigational Immunotherapy PATIENT PROFILE TREATMENT HISTORY TREATMENT RESPONSE 34 Evaluable patients 4 median prior lines 24% ov
Slide 15: BI-1808 in Combination with Pembrolizumab: Promising Efficacy in Ovarian Cancer
TNFR2 BI-1808 BI-1808 in Combination with Pembrolizumab: Promising Efficacy in Ovarian Cancer Summary of ESMO 2026 Ph 2a data (cut-off date Sep 14, 2026) • 24% ORR, 53% DCR in 34 evaluable patients: 1 complete response (CR), 7 partial response (PR) and several cases of stable disease (SD) exceeding
Slide 16: Phase 2a Part B - BI-1808 + Pembrolizumab in Ovarian Cancer
TNFR2 BI-1808 Phase 2a Part B -BI-1808 + Pembrolizumab in Ovarian Cancer Population distribution ccOC vs HGSA • Solid response signal in both clear cell and high-grade serous histology, with a very favorable safety profile. Less than AE- related 5% treatment discontinuations, and several patients ar
Slide 17: PFS Analysis in the Combination Cohort, RECIST v.1.1 vs iRECIST
TNFR2 BI-1808 PFS Analysis in the Combination Cohort, RECIST v.1.1 vs iRECIST RECIST criteria does not fully reflect long-term disease control or possibility of pseudo-progression • RECIST v. 1.1 criteria do not reflect long-term disease control, as does iRECIST criteria mPFS at 10.3 months. • As mo
Slide 18: Patient Population Comparison
TNFR2 BI-1808 Patient Population Comparison BI-1808 study population much heavier pretreated than the KEYNOTE-B96 population Characteristic BI-1808 KNB96 - pembro Differences • Compared to KEYNOTE-B96, patients in Study 19-BI-1808-01 were much heavier pretreated than N 34 322 - the KEYNOTE populatio
Slide 19: BI-1808 + pembrolizumab show response in a setting where IO has previously failed
BI-1808 + pembrolizumab show response in a setting where IO has previously failed to deliver • These results are impressive considering the heavy pretreatment history (median 4, range 1-10) prior lines. • Immuno-oncology agents (atezolizumab, avelumab, As a reference, the ADC Elahere response rate d
Slide 20: Treatment Paradigm Shaped by Platinum Sensitivity and Biomarker Status
TNFR2 BI-1808 The Treatment Paradigm is Shaped by Platinum Sensitivity and Biomarker Status; With Few Recent Approvals in PROC* Platinum Sensitive (PSOC) ≥6 months Platinum resistant (PROC) <6 months 1st Relapse 1L 2L 3L 4L+ mPFS ~5.5-8m mPFS ~4.4m Surgery Platinum doublet +/- Beva Paclitaxel, PLD,
Slide 21: The Treatment Paradigm is Changing with Few Recent Approvals in PROC
The Treatment Paradigm is Changing with Few Recent Approvals in PROC Isabelle Ray-Coquard & Kathleen N. Moore 21
Slide 22: ADCs are not a Competitive Threat — and They may Complement BI-1808
ADCs are not a Competitive Threat — and They may Complement BI-1808 Four structural limitations of the ADC class Significant toxicity Biomarker-restricted Near-universal Only two payload resistance classes Boxed warnings across the class: MIRV requires FRα-high — only Resistance develops in almost T
Slide 23: BI-1808 as the Next Standard of Care in Ovarian Cancer
BioInvent’s BI-1808 as the Next Standard of Care in Ovarian Cancer Estimated peak sales of BI-1808 in PROC of ~$1.7 billion (base-case) for current target product profile (TPP) CURRENT NEXT FORECAST • Standard of care (SoC) • BI-1808 on top of Region Peak Sales Peak Year in ovarian cancer the curren
Slide 24: Positioning BI-1808 in Recurring Ovarian Cancer
TNFR2 BI-1808 Positioning BI-1808 in Recurring Ovarian Cancer • First-in-class BI-1808 depletes immunosuppressive Tregs and reprograms macrophages to expand and activate CD8+ effector T cells, converting the tumor microenvironment from “cold" to “hot." • Pembrolizumab + paclitaxel achieved 53% ORR,
Slide 25: BI-1808 in CTCL
BI-1808 in CTCL ‘SBiolnvent | 2
Slide 26: Impressive Responses in Heavily Pre-treated PTCL or CTCL Patients
Impressive Responses Were Observed in Heavily Pre-treated Patients with PTCL or CTCL Treated with BI-1808 Monotherapy Case Studies PTCL Patient CTCL Patient (stage IV, 6 prior lines of treatment) (stage IIb MF, 5 prior lines of treatment) Baseline Week 9 Baseline Week 21 26
Slide 27: BI-1808 Clinical Phase 1/2a Study Overview
TNFR2 BI-1808 BI-1808 Clinical Phase 1/2a Study Overview Orphan Drug Designation • Safety and preliminary efficacy currently investigated in CTCL patients (sub-cohort of the ongoing Phase for TCL 2a clinical trial) Fast Track Designation for CTCL • 20 patients enrolled for BI-1808 1000 mg as single
Slide 28: BI-1808 Shows Promising Efficacy in CTCL (and PTCL)
TNFR2 BI-1808 BI-1808 Shows Promising Efficacy in CTCL (and PTCL) EHA 2026 poster Phase 2a monotherapy & combination data Single Agent (2A CTCL) — mSWAT + Pembrolizumab (2B CTCL) — mSWAT PTCL 40% 93% 1 CR 50% 75% 4 PR ORR DCR SS ongoing 2+ yrs ORR DCR 5 PRs + 1 CR 15 evaluable pts 4 PRs 8 evaluable
Slide 29: BI-1808 is Differentiated Where it Matters Most: Mycosis Fungoides
BI-1808 is Differentiated Where it Matters Most: Mycosis Fungoides MF represent the majority of CTCL patients (~70%), and where incumbents are weakest BI-1808 • Higher efficacy in MF than all other treatments except for brentuximab (30% of patients, black box warning) • No biomarker restriction • Be
Slide 30: BI-1808 Potential Path to Approval – US
TNFR2 BI-1808 BI-1808 Potential Path to Approval – US Breakthrough Designation Potential Timelines for Ovarian Cancer* Agreed Pivotal Design Fast Track Designation ✓ EOP Meeting ✓ Phase 2, Part A Randomized study in combo with monotherapy (n=20) Phase 2, Part B pembro and paclitaxel vs SoC Combo wit
Slide 31: A Pragmatic Development Strategy With Billion-Dollar Potential
A Pragmatic Development Strategy With Billion-Dollar Potential $ multi billion • Pursue Fast to market indication in CTCL (plan for BTD and accelerated approval) Other “cold” tumors • Develop triplet regimen with BI-1808 +pembrolizumab+paclitaxel in PROC Ovarian Cancer Earlier lines • Future develop
Slide 32: Anti-FcγRIIB
ANTI-FcγRIIB BI-1206 in Solid Tumors BI-1206 in Non-Hodgkin’s Lymphoma (NHL) 32
Slide 33: BI-1206 in Solid Tumors
BI-1206 in Solid Tumors: Non-Small Cell Lung Cancer Uveal Melanoma 33
Slide 34: BI-1206 with Pembrolizumab: Responses in Uveal Melanoma After Anti-PD-1 Failure
FcyRIIB BI-1206 Co-administration of BI-1206 with Pembrolizumab - Promising Responses in Uveal Melanoma who Previously Failed anti-PD-1 Baseline End of treatment 2 years Case study: PR 69 YO female with uveal melanoma. No response to prior immunotherapy or chemotherapy. Multiples lines of ICIs and C
Slide 35: BI-1206 with Pembrolizumab: Responses in Melanoma After Anti-PD-1 Failure
FcyRIIB Co-administration of BI-1206 with Pembrolizumab Promising Responses BI-1206 Observed in Melanoma, who Previously Failed Anti-PD-1 Therapy Baseline Scan at 16 months Case study: CR 77 YO male melanoma patient, stage IV. Deep Partial Response at first scan at 2 months, evolving to CR at 10 mon
Slide 36: Phase 2a Ongoing: BI-1206 + Keytruda in Treatment-Naïve Patients
FcyRIIB BI-1206 Phase 2a study Ongoing: BI-1206 + KEYTRUDA in Treatment-Naïve Patients • To evaluate safety and efficacy of BI-1206 in combination with pembrolizumab • Advanced or metastatic NSCLC and uveal melanoma • Patients will be enrolled at sites in Georgia, Germany, Poland, Romania, Spain, Sw
Slide 37: Competitive Landscape in PD-L1 High NSCLC
Competitive Landscape in PD-L1 High NSCLC BI-1206 + pembro opportunity Grey bubble: Non-approved Colored bubble: Approved Bubble size: No. of pts in reference trial 37
Slide 38: Positioning of BI-1206 in Non-Small Cell Lung Cancer
FcyRIIB BI-1206 Positioning of BI-1206 in Non-Small Cell Lung Cancer • BI-1206 blocks FcγRIIB (CD32b), a receptor on myeloid cells that actively removes anti-PD-1 antibodies off T-cells, internalizing and degrading them. By blocking FcγRIIB, BI-1206 prevents the removal of pembrolizumab from the T-c
Slide 39: BI-1206 in NHL
BI-1206 in NHL ‘YBiolnvent | 39
Slide 40: Paired with Rituximab, BI-1206 can Compete in a Highly Competitive FL Market
FcyRIIB BI-1206 Paired with Entrenched Rituximab, BI-1206 can Compete in a Highly Competitive FL Market Now Follicular Lymphoma (FL) Market Shifts Other MOA • Increasing bispecific options Bispecifics • Expansion of other MOAs (BTKi, CAR-T) Rituximab- based • Switch to rituximab biosimilars regimens
Slide 41: BI-1206 Clinical Study Overview
FcyRIIB BI-1206 BI-1206 Clinical Study Overview • Phase 1: BI-1206 enhances the activity of rituximab (next slide) • Phase 2a: Adding acalabrutinib to the combination results in impressive efficacy (and Safety!) Phase 1 Phase 2a BI-1206 + rituximab (Doublet) BI-1206 + rituximab + acalabrutinib (Trip
Slide 42: Triplet Combination Results in High Response Rates Across NHL Subtypes
FcyRIIB BI-1206 Triplet Combination Results in High Response Rates Across NHL Subtype No CRS · No ICANS 83% ORR (n=23) 48% CRR 100% DCR 81% ORR in FL (n=16) 44% CRR in FL No increased infection rate • ORR of 83%, CRR of 48% and DCR of 100% (n=23) • Best Response in 23 evaluable patients: – 11 comple
Slide 43: BI-1206 + Rituximab + Calquence Triplet: Best Response (FL, MZL, MCL)
FcyRIIB BI-1206 BI-1206 + Rituximab + Calquence* Triplet: Best Response (FL, MZL, MCL) PR * Acalabrutinib, supplied by AstraZeneca. Data cut-off 2026-05-06 43
Slide 44: BI-1206 in NHL: Potential Timelines
BI-1206 in NHL: Combination with Rituximab + Acalabrutinib - Potential Timelines *Type B FDA meeting Type B FDA meeting *Agreed Pivotal Phase 2 BLA submission design Breakthrough Therapy Designation Approval Phase 2a Signal Seeking Phase 2a follow up Pivotal Study - Phase 2*# (Submission in Q1) Conf
Slide 45: BI-1206 Positioning in Follicular Lymphoma
FcyRIIB BI-1206 BI-1206 Positioning in Follicular Lymphoma • In FL, repeated exposure to Rituximab leads to resistance via FcγRIIB-mediated internalization; BI-1206 blocks this escape route, potentially "resensitizing" the tumor to CD20 therapy even in heavily pre-treated patients. • While BTK inhib
Slide 46: Key Expected Milestones 2026-2027
Key Expected Milestones 2026-2027 2026 2027 ✓ Ovarian cancer TNFR2 ✓ Additional Phase First Phase 2a data Additional Phase 2a 2a data with triplet + Keytruda Keytruda data with Keytruda +Paclitaxel CTCL ✓ First Phase 2a data with Complete Phase 2a Keytruda + additional data dose optimization, Potent
Slide 47: www.bioinvent.com
* Biolnvent bringing antibodies to life
Slide 48: Appendix
Appendix 48
Slide 49: BioInvent Management Team
49 │ BioInvent Management Team Martin Welschof, Ph.D. Stefan Ericsson Andres McAllister, M.D., Ph.D. Björn Frendéus, Ph.D. Chief Executive Officer Chief Financial Officer Chief Medical Officer Chief Scientific Officer 8 28 9 25 Ashley Robinson Ingunn Munch Lindvig, Ph.D. Kristoffer Rudenholm Hansson
BioInvent International — Investor Presentation (October 2026) on 6ix